Cinacalcet hydrochloride: Treatment of hyperparathyroidism

Drugs of the Future

Volumn 27, Issue 9, 2002, Pages 831-836

  Sorbera, I A ^a   Castanera R M ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SENSING RECEPTOR; CINACALCET; G PROTEIN COUPLED RECEPTOR; GADOLINIUM; LANTHANUM; N [(1 NAPHTHYL)ETHYL] N [3 [3 (TRIFLUOROMETHYL)PHENYL]PROPYL]AMINE; NEOMYCIN; PARATHYROID HORMONE; R 568; SPERMINE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; EXTRACELLULAR CALCIUM; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE; MULTICENTER STUDY; PARATHYROID GLAND; PARATHYROID HORMONE RELEASE; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0036760041     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.09.695016     Document Type: Article

References (28)

1. Van Wagenen, B.C., Moe, S.T., Balandrin, M.F., DelMar, E.G., Nemeth, E.F. (NPS Pharmaceuticals, Inc.). Calcium receptoractive cpds. US 6211244.
2. Hyperparathyroidism. National Institute of Diabetes & Digestive & Kidney Diseases Web Site. September 12, 2002.
3. Columbia Presbyterian Medical Center Web Site. September 12, 2002.
4. 2+ and other ions as extracellular (first) messengers. Physiol Rev 1991, 71: 371-411.
5. 2+-sensing receptor from bovine parathyroid. Nature 1993, 366: 575-80.
6. Rogers, K.V., Dunn, C.K., Hebert, S.C., Brown, E.M. Localization of calcium receptor mRNA in the adult rat central nervous system by in situ hybridization. Brain Res 1997, 744: 47-56.
7. House, M.G., Kohlmeier, L., Chattopadhyay, N., Kifor, O., Yamaguchi, T., Leboff, M.S., Glowacki, J., Brown, E.M. Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res 1997, 12: 1959-70.
8. i signaling expressed by GCT23 osteoclast-like cells. Proc Assoc Am Physicians 1999, 111: 70-81.
9. Quarles, L.D. Cation sensing receptors in bone: A novel paradigm for regulating bone remodeling? J Bone Miner Res 1997, 12: 1971-4.
10. Pearce, S.H., Trump, D., Wooding, C. et al. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995, 96: 2683-92.
11. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993, 75: 1297-303.
12. Pollak, M.R., Seidman, C.E., Brown, E.M. Three inherited disorders of calcium sensing. Medicine (Baltimore) 1996, 75: 115-23.
13. 2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 1996, 5: 601-6.
14. Pearce, S.H., Williamson, C., Kifor, O. et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. New Engl J Med 1996, 335: 1115-22.
15. Gogusev, J., Duchambon, P., Hory, B., Giovannini, M., Goureau, Y., Sarfati, E., Drueke, T.B. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997, 51: 328-36.
16. Goodman, W.G., Frazao, J.M., Goodkin, D.A., Turner, S.A., Liu, W., Coburn, J.W. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000, 58: 436-45.
17. Wang, B., Osborn, K., Blaisdell, P., Brenner, R., Turner, S., Laycock, J., Mooney, J., Ghobarah, H., Arends, R. Pharmacokinetics (PK) of calcimimetic AMG 073 in secondary hyperparathyroidism (SHPT). Clin Pharmacol Ther 2001, 69(2): Abst PIII-107.
18. Shoback, D.M., Firek, A.F., Mims, R.B., Binder, T.A., Graves, T., Turner, S.A., Peacock, M. An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). J Bone Miner Res 2001, 16(Suppl. 1): Abst SA462.
19. Shoback, D.M., Bilezikian, J., Binder, T.A., Graves, T., Turner, S.A., Peacock, M. Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism. 22nd Annu Meet Am Soc Bone Miner Res (ASBMR) (Sept 22-26, Toronto) 2000, Abst F116.
20. Peacock, M., Shoback, D.M., Greth, W.E., Binder, T.A., Graves, T., Brenner, R.M., Turner, S.A., Marcus, R. The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J Bone Miner Res 2001, 16(Suppl 1): Abst 1106.
21. Peacock, M., Bilezekian, J.P., Turner, S.A., Guo, M.D., McCary, L.C., Koenig, K.G., Shoback, D.M. Long-term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism (PHPT). 84th Annu Meet Endocr Soc (June 1922, San Francisco) 2002, Abst OR21-1.
22. Goodman, W.G., Hladik, G.A., Turner, S.A., Blaisdell, P.W., Goodkin, D.A., Liu, W., Barri, Y.M., Cohen, R.M., Coburn, J.W. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002, 13: 1017-24.
23. Coburn, J.W., Barri, Y.M., Turner, S.A., Blaisdell, P.W., Goodkin, D.A., Liu, W., Goodman, W.G. Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2000, 11: Abst A3027.
24. Goodman, W.G., Hladik, G.A., Turner, S.A., Blaisdell, P.W., Goodkin, D.A., Liu, W., Cohen, R.M., Coburn, J.W. Multiple doses of the calcimimetic AMG 073 reduce plasma parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 2000, 11: Abst A3039.
25. Drueke, T., Cunningham, J., Goodman, W.G., Horl, W.H., Braun, J., Chen, M.-G., McCary, L.C., Steinhauslin-Jeanrenaud, F., Turner, S.A., Ritz, E. Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. ASN/ISN World Congr Nephrol (Oct 13-17, San Francisco) 2001, Abst A3992.
26. Lindberg, J.S., Moe, S.M., Goodman, W.G., Coburn, J.W., Turner, S.A., Blaisdell, P.W., McCary, L.C., Brenner, R.M., Liu, W., Martin, K.J. The calcimimetic AMG 073 reduces parathyroid hormone (PTH) phosphorus (P), and calcium X phosphorus product (Ca X P) in patients with ESRD and secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 2000, 11: Abst A3052.
27. Quarles, L.D., Sherrard, D.J., Adler, S., Rosansky, S.J., McCary, L.C., Brenner, R.M., Liu, W., Turner, S.A., Bushinsky, D.A. The calcimimetic AMG 073 reduces PTH and CaxP in patients with secondary hyperparathyroidism (SHPT). ASN/ISN World Congr Nephrol (Oct 13-17, San Francisco) 2001, Abst A4027.
28. Product pipeline. Amgen Web Site August 29, 2002.